{"id":393291,"date":"2021-05-13T14:52:06","date_gmt":"2021-05-13T17:52:06","guid":{"rendered":"https:\/\/revistapesquisa.fapesp.br\/?p=393291"},"modified":"2021-05-13T14:52:06","modified_gmt":"2021-05-13T17:52:06","slug":"antibodies-reduce-deaths","status":"publish","type":"post","link":"https:\/\/revistapesquisa.fapesp.br\/en\/antibodies-reduce-deaths\/","title":{"rendered":"Antibodies reduce deaths"},"content":{"rendered":"<p>A clinical trial led by researchers at the University of Oxford, UK, identified a second drug capable of reducing mortality among patients with severe COVID-19: monoclonal antibody tocilizumab, produced by Swiss pharmaceutical company Roche to treat arthritis. In the RECOVERY trial, the drug was given to 2,022 people with COVID-19 of varying severity and compared with conventional treatments offered to 2,094 participants. The mortality rate was 29% in the first group and 33% in the second, a reduction of four percentage points or 12%, according to an article yet to undergo peer review (<em>medRxiv<\/em>, February 11). Associated with the corticosteroid dexamethasone, which was the first drug confirmed effective against the disease, tocilizumab reduced deaths among patients receiving oxygen by cannula or mask by one-third, and among intubated patients by 50%.<\/p>\n","protected":false},"excerpt":{"rendered":"A clinical trial led by researchers at the University of Oxford, UK, identified a second drug capable of reducing mortality among patients with severe COVID-19","protected":false},"author":475,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1651],"tags":[210,242,247,260],"coauthors":[785],"class_list":["post-393291","post","type-post","status-publish","format-standard","hentry","category-notes","tag-cellular-biology","tag-immunology","tag-medicine","tag-public-health","keywords-coronavirus-en","keywords-covid-19-en","keywords-sars-cov-2-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/393291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/users\/475"}],"replies":[{"embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/comments?post=393291"}],"version-history":[{"count":2,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/393291\/revisions"}],"predecessor-version":[{"id":394029,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/393291\/revisions\/394029"}],"wp:attachment":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/media?parent=393291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/categories?post=393291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/tags?post=393291"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/coauthors?post=393291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}